All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-06-06T09:59:59.000Z

EHA2022 abstracts: What's hot in ALL?

By Abhilasha Verma
Jun 6, 2022
Share:

Bookmark this article

To help navigate the exciting content being presented at the EHA2022 Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies

P342

Baseline gene expression analysis of relapsed acute B-lymphoblastic leukemia patients treated with inotuzumab ozogamicin

P350

Blinatumomab and donor lymphocyte infusion (DLI) for molecular relapse after hematopoietic stem cell transplantation in pediatric patients

P355

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed B-cell acute lymphoblastic leukemia: updates from a phase II trial

P357

Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia (MPAL) diagnosed and treated in the last ten years. A CAMPUS-ALL study

P359

Improved overall survival and MRD clearance with blinatumomab vs chemotherapy as pre-transplant consolidation in pediatric high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL)

P368

A phase II study of inotuzumab ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia

P369

A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

P371

Hyper-CVAD with sequential blinatumomab, with or without inotuzumab ozogamicin, in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia

S111

Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial

S113

National pegaspargase-modified risk-oriented program for Philadelphia-negative adult acute lymphoblastic leukemia/lymphoblastic lymphoma (Ph− ALL/LL). GIMEMA LAL 1913 final results

S114

Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results from a phase II study

Treatment for relapsed/refractory ALL

P351

Dose-adjusted EPOCH + inotuzumab ozogamicin (DA-EPOCH-INO) is safe and active in adults with relapsed/refractory (R/R) B lymphoblastic leukemia (B-ALL): initial results of a phase I trial

P356

Subgroup analyses of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3

P360

Efficacy and safety of daratumumab in pediatric and young adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma: results from phase 2 DELPHINUS study

P370

Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

P372

Dismal outcomes of patients with relapsed/refractory B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab

P376

CD38: a functioning target in relapsed/refractory acute lymphoblastic leukemia. Limitations in treatment and diagnostics

P378

The prognosis factors of CAR-T therapy in patients with relapsed/refractory B-ALL

S110

A novel and successful CD7 gene knockout CAR-T cell therapy for relapsed or refractory T-cell hematologic malignancies

S112

Tisagenlecleucel in pediatric and young adult patients (pts) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study

Real-world evidence

P354

Real-world analysis of the risks of thrombotic and bleeding events in patients receiving pegylated asparaginase for treatment of acute lymphoblastic leukemia

P374

Blinatumomab as consolidation for adult B-cell precursor acute lymphoblastic leukemia. A real-world study

P375

Challenges in management of acute lymphoblastic leukaemia in a resource constrained setting in lower-middle-income countries (LMICS)


Biomarkers and biology

P307

Del(17)(q11) is typical marker of immature T-ALL of adults, with NF1, UTP6, and SUZ12 haploinsufficiency, genome instability, and gene downregulation

S105

In vivo PDX CRISPR/CAS9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance

S106

UBTF-ATXN7L3 gene fusion due to 17q21.31 deletion defines novel high-risk ALL subtype amenable to MRD-based treatment intensification

S107

SOD2 promotes acute leukemia adaptation to amino acid starvation through the N-degron pathway

S108

Pediatric T- ALL relapse: constitutional cancer predisposition and hypermutator phenotypes

S109

Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia

S253

The sheddase domain of ADAM10 augments the interaction of leukemia cells with the bone marrow niche in vivo as shown by reconstituting PDX leukemia cells with CRISPR-CAS9-induced knockout

EHA2022 abstracts

To download this document, click below.

Download here

More about...
EHA 2022

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox